DOMINANT OPTIC ATROPHY OPA1

Clinical trials for DOMINANT OPTIC ATROPHY OPA1 explained in plain language.

Never miss a new study

Get alerted when new DOMINANT OPTIC ATROPHY OPA1 trials appear

Sign up with your email to follow new studies for DOMINANT OPTIC ATROPHY OPA1, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Could vitamin B3 help save sight in rare optic nerve disease?

Disease control Ongoing

This study tests whether nicotinamide (vitamin B3) is safe and helpful for people with dominant optic atrophy (DOA), a genetic condition that slowly damages the optic nerve and causes vision loss. Researchers will give the vitamin to 25 adults with DOA and monitor for side effect…

Matched conditions: DOMINANT OPTIC ATROPHY OPA1

Phase: PHASE2, PHASE3 • Sponsor: University Hospital, Angers • Aim: Disease control

Last updated Jun 11, 2026 12:09 UTC

DOMINANT OPTIC ATROPHY OPA1

Get alerted when new DOMINANT OPTIC ATROPHY OPA1 trials appear

Could vitamin B3 help save sight in rare optic nerve disease?